AzTrials
AzTrials

Low Flow AnesthesiaNCT06611449

The Effect of Minimal Flow Anesthesia on Oxidative and Neuroendocrine Stress Response

A study testing The minimal flow anesthesia with sevoflurane group and The high flow anesthesia with sevoflurane group in people with Low Flow Anesthesia and Oxidative Stress, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Patients under general anesthesia who are unconscious and have stopped spontaneous breathing are actively ventilated with anesthesia machines, ensuring the anesthesia gas reaches the lungs and then the bloodstream. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
The minimal flow anesthesia with sevoflurane group and The high flow anesthesia with sevoflurane group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
1 siteTurkey (Türkiye)
Study dates
30 Jun 2024to Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • Ages 18-65
  • Scheduled for elective septorhinoplasty
  • ASA (physical status) 1-2

Who cannot join

  • • ASA (physical status) III-IV
  • Under 18 or over 65
  • Pregnant individuals
  • Serious cardiovascular disease or arrhythmia
  • Chronic obstructive pulmonary disease
  • Severe respiratory failure
Show all 15Show fewer
  • Uncontrolled cerebrovascular disease
  • Hepatic or renal dysfunction
  • Allergy to propofol, fentanyl, rocuronium, sevoflurane
  • Pituitary gland disease (e.g., pituitary adenoma)
  • Adrenal gland disease (e.g., pheochromocytoma, Cushing's disease)
  • Immune deficiency
  • Neuroendocrine system disease
  • BMI > 40
  • Patients who refuse to provide written informed consent.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Bezmialem Vakif University

    Istanbul, Fatih, 34093

Other trials in Turkey (Türkiye)

About this study

Patients under general anesthesia who are unconscious and have stopped spontaneous breathing are actively ventilated with anesthesia machines, ensuring the anesthesia gas reaches the lungs and then the bloodstream. Not all the gas reaching the lungs during respiration is used; a small portion is absorbed by the body, and most of it is expelled during exhalation. After eliminating the carbon dioxide in the expired gas, it is more suitable to re-breathe the remaining gas. The portion taken by the patient needs to be provided for the next breath, and this added gas is called "fresh gas flow." Today, low flow anesthesia is defined when the fresh gas flow rate is 0.5-1 L/min, minimal flow anesthesia when it is 0.25-0.5 L/min, and metabolic flow anesthesia when it is 0.25 L/min. Our study will evaluate the effects of minimal flow anesthesia, which is widely used today due to its advantages, on oxidative stress and neuroendocrine stress response

Read the detailed description

General anesthesia is characterized by anesthesia, analgesia, amnesia, and muscle relaxation. The most common practice today for maintaining anesthesia after induction is to add a low-density effective inhalation anesthetic to an oxygen/air mixture. Patients who are unconscious and have stopped spontaneous breathing are actively ventilated with anesthesia machines, ensuring the anesthesia gas reaches the lungs and then the bloodstream. Minute ventilation refers to the total amount of gas (oxygen, air, and anesthetic agent mixture) a patient breathes in one minute, which is approximately 5-6 L in a normal adult weighing 70 kg.

During respiration, not all the gas reaching the lungs is used; a small portion is absorbed by the body, and most of it is expelled during exhalation. After eliminating the carbon dioxide in the expired gas, it is more suitable to re-breathe the remaining gas for lung physiology, environmental protection, and cost-effectiveness. The portion taken by the patient needs to be provided for the next breath, and this added gas is called "fresh gas flow."

Today, in adults, low flow anesthesia is defined when the fresh gas flow rate is 0.5-1 L/min, minimal flow anesthesia when it is 0.25-0.5 L/min, and metabolic flow anesthesia when it is 0.25 L/min. Reducing the fresh gas flow has positive effects on the patient's health under anesthesia, environmental protection, and cost-effectiveness, as well as reducing pathologies in the operating room staff due to air pollution. Low flow anesthesia has been shown to have no adverse effects on oxygenation, ventilation, organ functions, or hemodynamic parameters. It does not affect any surgical procedure.

The acute stress response associated with surgery and anesthesia is connected to the neuroendocrine-metabolic system and the inflammatory-immune system. In response to surgical stress, adrenocorticotropic hormone(ACTH) is released from the pituitary gland via corticotropin-releasing hormone(CRH). ACTH stimulates the adrenal cortex to release glucocorticoid (cortisol). Both innate and adaptive immune cells play a role in the stress response to surgery. Cytokines mediate the local inflammatory response seen with tissue damage. Pro-inflammatory cytokines, such as interleukin-6 (IL-6), are released, peaking in the first 24 hours post-surgery.

Previous studies have shown an increase in cortisol, ACTH, and IL-6 values on the first postoperative day; their changes were recorded by measuring them at induction, the end of surgery, and at postoperative 12 and 24 hours. The body contains unstable molecules defined as free oxygen radicals. These molecules are balanced by antioxidant molecules. The imbalance in favor of oxidants leads to oxidative stress, causing a series of tissue damage. The biochemical markers indicating this balance are total antioxidant status (TAS) and total oxidative status (TOS).

Our study will evaluate the effects of minimal flow anesthesia, which is widely used today due to its advantages, on oxidative stress and neuroendocrine stress response.

*Research Methodology* Our research is a prospective, randomized controlled clinical study. Patients aged 18-65 undergoing elective septorhinoplasty classified as American Society of Anesthesiologists(ASA) 1-2 will be included. Informed consent will be obtained from patients who volunteer for the study.

Patients included in the study will be divided into two groups using a closed envelope method. After reaching a minimum alveolar concentration (MAC) value of 0.9-1.0, group 1 (minimal flow group) (n=16) will receive maintenance anesthesia with minimal fresh gas flow, and group 2 (high flow group) (n=16) will receive maintenance anesthesia with high fresh gas flow. Group 1 will receive maintenance anesthesia with 80-100% O2 and 3.5-4.5% sevoflurane at a fresh gas flow rate of 0.3-0.4 L/min. Group 2 will receive maintenance anesthesia with 40-45% oxygen-air mixture, 2-2.5% sevoflurane, and a fresh gas flow rate of 4 L/min.

Levels of Total Antioxidant Status (TAS), Total Oxidative Status (TOS), ACTH (adrenocorticotropic hormone), cortisol, and IL-6 (inflammatory cytokine) will be measured from blood samples taken from the patients. Before the surgery, a 20-gauge venous cannula will be placed in the antecubital region for blood sampling to avoid repeated invasive procedures. Immediately before the surgery, 8 ml of blood will be taken as the first sample. The sample will be placed in 3 ml ethylenediaminetetraacetic acid (EDTA) and 5 ml gel tubes and sent to the biochemistry laboratory to be stored at -80°C. At the end of surgery, 5 ml of blood will be taken as the second sample before extubation, placed in a gel tube, and sent to the biochemistry laboratory to be stored at -80°C. At the 6th postoperative hour, 8 ml of blood will be taken as the third sample, placed in 3 ml EDTA and 5 ml gel tubes, and sent to the biochemistry laboratory to be stored at -80°C. At the 18th postoperative hour, 8 ml of blood will be taken as the fourth sample, placed in 3 ml EDTA and 5 ml gel tubes, and sent to the biochemistry laboratory to be stored at -80°C. A total of 30 ml of blood samples will be collected from the patient. The blood samples will be centrifuged at 3000 rpm for 10 minutes, and the separated sera will be stored at -80°C for analysis.

Patients will be discharged with appropriate treatment deemed suitable by the surgical team. The levels of Total Oxidative Status (TOS), Total Antioxidant Status (TAS), ACTH (adrenocorticotropic hormone), cortisol, and IL-6 (inflammatory cytokine) will be measured in the blood sample taken before induction. TAS/TOS will be measured in the second blood sample taken at the end of the surgery. Total Oxidative Status (TOS), Total Antioxidant Status (TAS), ACTH (adrenocorticotropic hormone), cortisol, and IL-6 (inflammatory cytokine) will be measured in blood samples taken at the 6th and 18th postoperative hours. Hemodynamic parameters, visual analogue pain score (VAS), and nausea-vomiting status will be recorded at the 6th and 18th postoperative hours. After centrifuging the blood samples, they will be stored at -80°C, and the specified biomarkers will be evaluated in the laboratory after all samples are collected. The results will be used in our research after statistical analysis.

Data will be analyzed using the Statistical Package for the Social Sciences(SPSS)-statistics 22.0 software package. Categorical variables will be expressed as numbers and percentages, while continuous variables will be presented as median, mean, and standard deviation. The chi-square test will be used to compare differences between categorical variables. The normal distribution of continuous variables will be assessed by the Shapiro-Wilk test. The Student's t-test will be used for parametric data and the Mann-Whitney U test for non-parametric data to compare continuous variables between the two groups. A p-value of <0.05 will be considered significant in all tests.

Being tested
The minimal flow anesthesia with sevoflurane group, The high flow anesthesia with sevoflurane group
Keywords
Low Flow Anesthesia, Oxidative Stress, Neuroinflammatory Response

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • The minimal flow anesthesia with sevoflurane groupOther

    In the minimal flow group, anesthesia will be maintained with minimal fresh gas flow (0.3-0.5 L/min). The effect of minimal flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.

    Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery.

  • The high flow anesthesia with sevoflurane groupOther

    Maintenance of anesthesia in the high flow group will be provided with a high fresh gas flow (4 L/min). The effect of high flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.

    Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery.

Study groups in NCT06611449
Study groupRoleWhat they receive
The minimal flow groupActive comparatorAs soon as mechanical ventilation begins, sevoflurane at a concentration of 3% and a fresh gas flow of 4 L/min with 40-45% oxygen will be used to maintain ventilation until the MAC value reaches 0.9-1.0 For patients in Group 1:the minimal flow group (n=16), maintenance anesthesia will be provided with 80-100% O2 and 3.5-4.5% sevoflurane at a fresh gas flow rate of 0.3-0.5 L/min(minimal fresh gas flow anesthesia) Near the end of the operation, the maintenance anesthetics will be discontinued, and the fresh gas flow will be increased to 6 L/min
Receives: Other: The minimal flow anesthesia with sevoflurane group
The high flow groupActive comparatorAs soon as mechanical ventilation begins, sevoflurane at a concentration of 3% and a fresh gas flow of 4 L/min with 40-45% oxygen will be used to maintain ventilation until the MAC value reaches 0.9-1.0 For patients in Group 2: the high flow group (n=16), maintenance anesthesia will be provided with a 40-45% oxygen-air mixture, 2-2,5% sevoflurane, and a fresh gas flow rate of 4 L/min (high fresh gas flow anesthesia) Near the end of the operation, the maintenance anesthetics will be discontinued, and the fresh gas flow will be increased to 6 L/min
Receives: Other: The high flow anesthesia with sevoflurane group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Interleukin 6 (IL-6) level

    Proinflammatory cytokines (Biochemical marker)

    Measured: Just before surgery begins, postoperative 6th hour and postoperative 18th hour

  2. Adrenocorticotropic hormone (ACTH) level

    Adrenocorticotropic hormone(Biochemical marker)

    Measured: Just before surgery begins, postoperative 6th hour and postoperative 18th hour

  3. Cortisol level

    Biochemical marker

    Measured: Just before surgery begins, postoperative 6th hour and postoperative 18th hour

  4. Total oxidative status (TOS) Level

    Total oxidative status; blood biochemical tests are used to calculate oxidative indicators.

    Measured: Just before surgery begins, end of surgery, postoperative 6th hour and postoperative 18th hour

  5. Total antioxidative status( TAS) Level

    Total antioxidative status; blood biochemical tests are used to calculate oxidative indicators.

    Measured: Just before surgery begins, end of surgery, postoperative 6th hour and postoperative 18th hour

Secondary outcomes (6)
  1. amount of bleeding

    Total amount of bleeding at the end of surgery

    Measured: end of surgery

  2. Amount of volatile anesthetic use

    Total amount of volatile anesthetic used at the end of anesthesia

    Measured: End of anesthesia

  3. Body temperature change

    Body temperature measured from the axillary region

    Measured: From the beginning of anesthesia to the 18th postoperative hour

  4. The presence of nausea and vomiting

    The presence and frequency of nausea and vomiting

    Measured: From the recovery of anesthesia to the 18th postoperative hour

  5. Assessment of pain

    The severity of the patient's pain is queried according to the visual pain score. The Visual Analog Scale (VAS) is a subjective measure used to assess the intensity of pain a person is experiencing. It consists of a straight line, usually 10 centimeters long, with one end defined as "no pain" and the other end as "worst imaginable pain." Patients are asked to mark a point on this line. As the numerical value increases from 1 to 10, the intensity of the pain increases.

    Measured: From the recovery of anesthesia to the 18th postoperative hour

  6. Adverse events

    bronchospasm, hypoxemia, airway edema, hypotension, bradycardia, massive bleeding

    Measured: From the recovery of anesthesia to the 18th postoperative hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2024
  2. Study start30 Jun 2024
  3. Primary completionNov 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
2 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06611449
Sponsor's protocol ID
hdeniz.001
Status last verified
Sep 2024
First submitted
30 May 2024
Last updated
25 Sep 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Cusack B, Buggy DJ. Anaesthesia, analgesia, and the surgical stress response. BJA Educ. 2020 Sep;20(9):321-328. doi: 10.1016/j.bjae.2020.04.006. Epub 2020 Jul 21. No abstract available.

    PubMed 33456967
  • Kasikara H, Dumanli Ozcan AT, Bicer CK, Senat A, Yalcin A, Altin C, Mustafa Aksoy S, But A. The effect of low flow anesthesia with sevoflurane on oxidative status: A prospective, randomized study. Saudi Med J. 2022 Mar;43(3):227-235. doi: 10.15537/smj.2022.43.3.20210876.

    PubMed 35256489

Questions about this trial

What is this clinical trial studying?

A study testing The minimal flow anesthesia with sevoflurane group and The high flow anesthesia with sevoflurane group in people with Low Flow Anesthesia and Oxidative Stress, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Interleukin 6 (IL-6) level (time frame: Just before surgery begins, postoperative 6th hour and postoperative 18th hour). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06611449, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in